[{"orgOrder":0,"company":"Pharmascience Inc.","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Plant Extract\/Herbal","year":"2021","type":"Inapplicable","leadProduct":"Colchicine","moa":"Tubulin","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Pharmascience Inc.","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Pharmascience Inc. \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pharmascience Inc. \/ Inapplicable"},{"orgOrder":0,"company":"PENDOPHARM DIVISION OF DE PHARMASCIENCE INC","sponsor":"PENDOPHARM DIVISION OF DE PHARMASCIENCE INC","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Plant Extract\/Herbal","year":"2021","type":"Inapplicable","leadProduct":"Colchicine","moa":"Tubulin","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"PENDOPHARM DIVISION OF DE PHARMASCIENCE INC","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"PENDOPHARM DIVISION OF DE PHARMASCIENCE INC \/ PENDOPHARM DIVISION OF DE PHARMASCIENCE INC","highestDevelopmentStatusID":"15","companyTruncated":"PENDOPHARM DIVISION OF DE PHARMASCIENCE INC \/ PENDOPHARM DIVISION OF DE PHARMASCIENCE INC"},{"orgOrder":0,"company":"Pharmascience Inc.","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Teriflunomide","moa":"Dihydroorotate dehydrogenase","graph1":"Neurology","graph2":"Approved FDF","graph3":"Pharmascience Inc.","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Pharmascience Inc. \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pharmascience Inc. \/ Inapplicable"},{"orgOrder":0,"company":"Pharmascience Inc.","sponsor":"Pharmascience Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Plant Extract\/Herbal","year":"2021","type":"Inapplicable","leadProduct":"Colchicine","moa":"Tubulin","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Pharmascience Inc.","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pharmascience Inc. \/ Pharmascience Inc.","highestDevelopmentStatusID":"10","companyTruncated":"Pharmascience Inc. \/ Pharmascience Inc."},{"orgOrder":0,"company":"Pharmascience Inc.","sponsor":"Pharmascience Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Plant Extract\/Herbal","year":"2020","type":"Inapplicable","leadProduct":"Colchicine","moa":"Tubulin","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Pharmascience Inc.","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pharmascience Inc. \/ Pharmascience Inc.","highestDevelopmentStatusID":"10","companyTruncated":"Pharmascience Inc. \/ Pharmascience Inc."},{"orgOrder":0,"company":"Pharmascience Inc.","sponsor":"Pharmascience Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Plant Extract\/Herbal","year":"2020","type":"Inapplicable","leadProduct":"Colchicine","moa":"Tubulin","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Pharmascience Inc.","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pharmascience Inc. \/ Pharmascience Inc.","highestDevelopmentStatusID":"10","companyTruncated":"Pharmascience Inc. \/ Pharmascience Inc."},{"orgOrder":0,"company":"Pharmascience Inc.","sponsor":"Pharmascience Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Plant Extract\/Herbal","year":"2020","type":"Inapplicable","leadProduct":"Colchicine","moa":"Tubulin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Pharmascience Inc.","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pharmascience Inc. \/ Pharmascience Inc.","highestDevelopmentStatusID":"10","companyTruncated":"Pharmascience Inc. \/ Pharmascience Inc."}]

Find Clinical Drug Pipeline Developments & Deals by Pharmascience Inc.

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharmaconex
                          Not Confirmed
                          Pharmaconex
                          Not Confirmed

                          Details : Aubagio-Generic (teriflunomide) is an immunomodulatory agent with anti-inflammatory properties, inhibits dihydroorotate dehydrogenase. It is indicated for the treatment of patients with relapsing remitting multiple sclerosis.

                          Product Name : pms-Teriflunomide

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          May 27, 2022

                          Lead Product(s) : Teriflunomide

                          Therapeutic Area : Neurology

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          Pharmaconex
                          Not Confirmed
                          Pharmaconex
                          Not Confirmed

                          Details : Myinfla (colchicine 0.5 mg extended-release tablets) inhibits the Beta tubulin polymerisation, which is indicated for the reduction of atherothrombotic events in adult patients with existing coronary artery disease.

                          Product Name : Myinfla

                          Product Type : Plant Extract/Herbal

                          Upfront Cash : Inapplicable

                          September 22, 2021

                          Lead Product(s) : Colchicine

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          Pharmaconex
                          Not Confirmed
                          Pharmaconex
                          Not Confirmed

                          Details : Health Canada has issued a Notice of Compliance for the prescription drug MYINFLA™ (colchicine 0.5 mg tablets) based on the results of the Montreal Heart Institute (MHI)’s COLCOT clinical trial.

                          Product Name : Myinfla

                          Product Type : Plant Extract/Herbal

                          Upfront Cash : Inapplicable

                          August 27, 2021

                          Lead Product(s) : Colchicine

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Approved FDF

                          Recipient : Montreal Heart Institute

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          Pharmaconex
                          Not Confirmed
                          Pharmaconex
                          Not Confirmed

                          Details : Colchicine tablets inhibits the beta tubulin polymerisation, which is investigated for the treatment of COVID-19 infection in non-hospitalized patients.

                          Product Name : Myinfla

                          Product Type : Plant Extract/Herbal

                          Upfront Cash : Inapplicable

                          January 23, 2021

                          Lead Product(s) : Colchicine

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase III

                          Recipient : Montreal Heart Institute

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          Pharmaconex
                          Not Confirmed
                          Pharmaconex
                          Not Confirmed

                          Details : Colchicine tablets inhibits the beta tubulin polymerisation, which is investigated for the treatment of COVID-19 infection in non-hospitalized patients.

                          Product Name : Myinfla

                          Product Type : Plant Extract/Herbal

                          Upfront Cash : Inapplicable

                          November 29, 2020

                          Lead Product(s) : Colchicine

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase III

                          Recipient : Montreal Heart Institute

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          Pharmaconex
                          Not Confirmed
                          Pharmaconex
                          Not Confirmed

                          Details : The first of these sub analyses simultaneously published in the European Heart Journal reveals that early initiation of low-dose colchicine within the first 3 days after MI significantly reduces the risk of ischemic CV events by 48% as vs placebo on top ...

                          Product Name : Myinfla

                          Product Type : Plant Extract/Herbal

                          Upfront Cash : Inapplicable

                          August 31, 2020

                          Lead Product(s) : Colchicine

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase III

                          Recipient : Montreal Heart Institute

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          Pharmaconex
                          Not Confirmed
                          Pharmaconex
                          Not Confirmed

                          Details : Colchicine tablets inhibits the beta tubulin polymerisation, which is investigated for the treatment of COVID-19 infection in non-hospitalized patients.

                          Product Name : Myinfla

                          Product Type : Plant Extract/Herbal

                          Upfront Cash : Inapplicable

                          January 30, 2020

                          Lead Product(s) : Colchicine

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase III

                          Recipient : Montreal Heart Institute

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          Pharmaconex
                          Not Confirmed
                          Pharmaconex
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          August 06, 2019

                          Lead Product(s) : Cholestyramine

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          Process Development
                          Not Confirmed
                          Process Development
                          Not Confirmed

                          Lead Product(s) : Decitabine

                          Therapeutic Area : Oncology

                          Study Phase : Phase I/ Phase II

                          Sponsor : Royal DSM | MDEIE Ministry, Québec Government | INRS-Institut Armand Frappier

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Cytotoxic Drug

                          Upfront Cash : Inapplicable

                          June 26, 2012

                          Lead Product(s) : Decitabine

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Royal DSM | MDEIE Ministry, Québec Government | INRS-Institut Armand Frappier

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank